Trefoil completes series A funding supporting corneal disease treatment

Trefoil Therapeutics has raised $28 million in Series A financing, which will be used to support its phase 2a proof-of-concept study in corneal endothelial dystrophy, the company announced in a press release.

Leave a Reply

Your email address will not be published. Required fields are marked *